By Dean Seal
Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia.
The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago.
The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510(k) clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia.
This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 20, 2025 10:20 ET (14:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。